Medication info
Mebitan Tablets (Memantine Hydrochloride)

Mebitan Tablets (Memantine Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Memantine Hydrochloride›10mg / 1 tablet
Manufacturer / importer
Korea United Pharm Co., Ltd.
Appearance
White to off-white oblong film-coated tablets
Packaging
Domestic: 30 tablets/bottle, 100 tablets/bottle Export: 30 tablets (10 tablets/PTPX3)
Approval status
Active

MFDS item code 200600358 · Notified 2006.03.03 · Insurance code 644301130

Summary

Main use
Treatment of moderate to severe Alzheimer’s disease
Who takes it
Adults
Adult dose
This medicine is taken orally once daily at the same time each day. If necessary, it may be taken twice daily. It may be taken with or without food. Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows until the maintenance dose is reached. Week 1 (Days 1–7): Administer 5mg once daily for 7 days. Week 2 (Days 8–14): Administer 10mg once daily for 7 days. Week 3 (Days 15–21): Administer 15mg once daily for 7 days. From Week 4 onward: Administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg once daily. Based on clinical data, the recommended dose for elderly patients aged 65 years or older is 20mg once daily. No dose adjustment is required in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-49 mL/min), the daily dose should be reduced to 10mg. If well tolerated after at least 7 days of treatment, the dose may be increased to 20mg daily according to the standard dose-escalation regimen. In patients with severe renal impairment (creatinine clearance 5-29 mL/min), the daily dose should be reduced to 10mg. No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine to these patients.

Ingredients

Manufacturer
Korea United Pharm Co., Ltd.

Efficacy & effects

Treatment of moderate to severe Alzheimer’s disease

  • Alzheimer's disease
View approved original text

This medication is used in the treatment of moderate to severe Alzheimer's disease. It can improve cognitive function in Alzheimer's patients and assist in enhancing daily living abilities. It helps slow the progression of symptoms and contributes to improving the quality of life for patients.

How to take

Adult dose

This medicine is taken orally once daily at the same time each day. If necessary, it may be taken twice daily. It may be taken with or without food. Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows until the maintenance dose is reached. Week 1 (Days 1–7): Administer 5mg once daily for 7 days. Week 2 (Days 8–14): Administer 10mg once daily for 7 days. Week 3 (Days 15–21): Administer 15mg once daily for 7 days. From Week 4 onward: Administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg once daily. Based on clinical data, the recommended dose for elderly patients aged 65 years or older is 20mg once daily. No dose adjustment is required in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-49 mL/min), the daily dose should be reduced to 10mg. If well tolerated after at least 7 days of treatment, the dose may be increased to 20mg daily according to the standard dose-escalation regimen. In patients with severe renal impairment (creatinine clearance 5-29 mL/min), the daily dose should be reduced to 10mg. No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine to these patients.

Precautions

This medication should not be used by patients with hypersensitivity to the ingredient or those with severe liver or kidney dysfunction. Patients with epilepsy or a history of seizures should be particularly cautious when using this medication, as the risk of side effects may increase when taken with certain other medications. Patients who may experience alterations in urinary pH or those with cardiovascular disease should be closely monitored while using this medication. Side effects such as dizziness, headache, constipation, drowsiness, and hypertension may occur during treatment, so any unusual symptoms should be discussed with healthcare providers. There may be potential drug interactions, so it is essential to inform healthcare providers of any medications currently being taken, especially in cases of co-administration with NMDA antagonists, antipsychotics, skeletal muscle relaxants, anticoagulants, etc. Women who are pregnant or may become pregnant should consider the risks to the fetus associated with the use of this medication, weighing the benefits and risks adequately. For breastfeeding mothers, it is recommended to discontinue breastfeeding as this medication may pass into breast milk. Safety and efficacy have not been established for pediatric and adolescent patients under 18 years of age, and use in this population is not recommended. In cases of overdose, symptoms such as confusion, drowsiness, dizziness, and vomiting may occur; thus, if an overdose is suspected, immediate medical attention should be sought for appropriate treatment. This medication may impair the speed of response and concentration, so caution is advised when driving or operating machinery. Keep out of reach of children and store in the original container to maintain quality.

Side effects

  • Dizziness
  • headache
  • constipation
  • drowsiness
  • hypertension
  • fungal infection
  • drug allergy
  • confusion
  • hallucinations
  • psychotic reactions
Show 24 more
  • balance disorder
  • gait abnormalities
  • seizures
  • heart failure
  • venous thromboembolism
  • dyspnea
  • vomiting
  • pancreatitis
  • elevated liver function tests
  • hepatitis
  • fatigue
  • nonspecific fatigue
  • weakness
  • diarrhea
  • anxiety
  • aggression
  • delirium
  • unresponsiveness
  • restlessness
  • psychosis
  • visual disturbances
  • convulsions
  • coma
  • double vision

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to prevent air ingress, at room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the medication's efficacy and use safely.

Appearance and packaging

Appearance

White to off-white oblong film-coated tablets

Package unit

Domestic: 30 tablets/bottle, 100 tablets/bottle Export: 30 tablets (10 tablets/PTPX3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.